New Antibiotic registered to treat Urinary Tract Infections (UTI)
Updated: Nov 16, 2020
MacroBID® is a new antibiotic medicine Medsafe registered by Te Arai BioFarma.
MacroBID® is a prolonged release nitrofurantoin containing nitrofurantoin macrocrystals and nitrofurantoin monohydrate for the treatment of acute, symptomatic, uncomplicated UTIs.
MacroBID® allows convenient twice daily dosing.
MacroBID® will be fully funded by PHARMAC from 1 March 2021 following a high priority recommendation based on improved compliance, reduced side effects and a lower risk of resistance.
"Antibiotic stewardship is extremely important for all societies across the world. For this reason, it was viewed as important to make available a twice daily formulation of nitrofurantoin which is recommended as first line treatment for acute UTIs. Through a long-term collaboration with an important international partner, Te Arai BioFarma has successfully made MacroBID® available to New Zealand patients." Scott Lissington COO, Te Arai BioFarma.
For more information please contact:
Te Arai BioFarma Ltd 0800 TE ARAI
MacroBID® is a Prescription Medicine. For full information please consult the Medsafe website and product data sheet at www.medsafe.govt.nz. MacroBID® is a registered Trademark of the Alvogen Group of companies.
Te Arai BioFarma is a New Zealand owned family company created to improve access to Medicines for New Zealanders.
10 views0 comments